Introduction
============

Lupus nephritis (LN) is one of the most common clinical manifestations and serious complications in patients with systemic lupus erythematosus (SLE). Almost all patients with SLE have renal damage in the course of their disease and 25--50% of patients have clinical manifestations of nephropathy at the time of diagnosis ([@b1-etm-0-0-8257]). In recent years, due to early diagnosis and comprehensive treatment, the survival rate of patients with LN has significantly improved, but in certain patients, traditional immunosuppressive agents are still ineffective. Indeed, \~30% of treated patients fail to improve and certain patients develop refractory LN (RLN) after one year of traditional treatment ([@b2-etm-0-0-8257]).

Patients with RLN have been indicated to display no serum creatinine improvement after 2--3 months under the traditional treatment regimen \[cyclophosphamide (CTX) + glucocorticoids (GC)\] or no proteinuria or albumin improvement after 6 months ([@b3-etm-0-0-8257],[@b4-etm-0-0-8257]). According to the World Health Organization, LN may be classified into 6 categories based on renal biopsy, ranging from type I to type VI and the respective prognosis is in the order from good to bad. In general, patients with class III, IV, V, III+V and IV+V LN are prone to develop RLN. A cohort study in Egypt indicated that patients with class II LN had a complete response to treatment and \~27.3% of patients with class III, IV and V LN did not respond to treatment ([@b5-etm-0-0-8257]). Patients with LN who do not respond to treatment tend to have more irreversible injuries and the condition is more likely to deteriorate in such patients. A cohort study from a Chinese population suggested that the treatment was ineffective in \~26.5% of the population and they eventually developed end-stage renal failure ([@b6-etm-0-0-8257]). Another study suggested that failure to respond after treatment for one year was an independent predictor of mortality in patients with LN ([@b7-etm-0-0-8257]).

If the traditional treatment regimen fails, such as if there is no response after 6 months of treatment, the patient has refractory LN ([@b8-etm-0-0-8257]). In this case, a large number of novel pharmaceutical preparations, including mycophenolate mofetil (MMF), tacrolimus (TAC) and rituximab (RTX), have been developed in China and elsewhere, and these drugs were reported to have a certain therapeutic effect in RLN. However, there are no studies that evaluate the best treatment for RLN. Therefore, the present meta-analysis study aimed to systematically evaluate the effectiveness and safety of common therapeutic drugs for the treatment of RLN and screen the optimal therapeutic drugs or regimens to provide a basis for the clinical treatment of RLN.

Materials and methods
=====================

### Search strategy

The PubMed, Embase, Cochrane Library, China Knowledge Network Infrastructure, VIP and Wanfang databases were searched from inception to April 30, 2018. The search terms include 'refractory', 'lupus nephritis' and 'treatment'. The search strategy was adjusted according to the different databases. The title and abstract of the citations were screened first, and then the full text was screened. In addition, the references were manually checked in published reviews to thoroughly search the literature.

### Inclusion and exclusion criteria

The following publication references were included in the present study: i) Subjects, patients with refractory lupus nephritis; ii) randomized controlled trials (RCTs); iii) observation group or control group containing ≥1 of the following drugs: Glucocorticoids, cyclophosphamide, mycophenolate mofetil, tacrolimus, leflunomide, cyclosporine A and/or rituximab; and iv) available data, effectiveness or adverse reactions. However, studies on animal models, crossover studies, case reports and studies without sufficient data were excluded.

### Data extraction and quality assessment

Then, two reviewers independently screened and crosschecked the literature. In case of disagreement, the discussion was resolved or submitted to a third researcher. Duplicates were removed, and unrelated literature was excluded by reading the title and abstract. Then, the citations were determined by reading the full text. The collected data mainly included indicators of effectiveness i.e. complete remission (CR) and partial remission (PR); evaluation criteria for effectiveness, i.e. 24-h urine protein \<0.3 g/l for CR, and 24-h urine protein \<1.0 g/l, serum albumin \>30 g/l and serum creatinine \<25% for PR; the total number of cases with effective treatment was determined as the number of cases with CR + number of cases with PR ([@b9-etm-0-0-8257]). The safety indicators were infection and other adverse reactions including gastrointestinal reactions, leukopenia, liver damage and bone marrow suppression. The Jadad scoring standard was used to quantitatively evaluate the quality of the included studies. The score ranged from 0 to 5; a total score of ≥4 indicated high quality ([@b10-etm-0-0-8257]).

### Statistical analysis

Stata 14.0 software (Stata Corp.) was used in the present Network Meta Analysis (NMA). The odds ratio and 95% CI were determined to compare the efficacy and adverse reactions of the nine treatment regimens for RLN. The degree of heterogeneity was quantified using I^2^ calculations. Values of I^2^\<50% were considered to indicate no heterogeneity. The analysis was performed using the fixed-effects model or random-effects model as appropriate. Furthermore, a sensitivity analysis was performed by omitting studies one by one to determine the source of heterogeneity. The P-value of the Z test was used to assess the direct and indirect comparison results in NMA ([@b11-etm-0-0-8257]). If P\>0.05, the direct comparison result is consistent with the indirect comparison result; otherwise it is inconsistent. The efficacy and adverse reaction risks of each treatment regimen were sequenced using the surface under the cumulative ranking curve (SUCRA) and the optimal treatment protocol was determined.

Results
=======

### Selection of studies for inclusion

A total of 1,366 relevant articles were initially retrieved, of which 494 duplicated articles and 819 studies (87 reviews, 112 animal experiments and 620 non-randomized controlled trials) were excluded after reading their titles and abstracts. In addition, 34 articles did not meet the inclusion criteria and were also excluded. Finally, 19 articles comprising a total of 1,127 patients were included ([Fig. 1](#f1-etm-0-0-8257){ref-type="fig"}).

### Studies included in the meta-analysis

Among the 19 articles, 17 were in Chinese ([@b9-etm-0-0-8257],[@b12-etm-0-0-8257]--[@b27-etm-0-0-8257]) and 2 were in English ([@b28-etm-0-0-8257],[@b29-etm-0-0-8257]). Except for one study that was a three-arm study ([@b26-etm-0-0-8257]), the remaining 18 were two-arm studies. Only three studies ([@b7-etm-0-0-8257],[@b21-etm-0-0-8257],[@b25-etm-0-0-8257]) were identified as high-quality studies (Jadad score=4). A total of seven therapeutic drugs were used in nine different treatment regimes. The basic characteristics of the studies included and the treatment regimens are specified in [Table I](#tI-etm-0-0-8257){ref-type="table"}. [Fig. 2](#f2-etm-0-0-8257){ref-type="fig"} shows the sample size for each treatment regimen and the number of studies compared between the two regimens, such as the largest number of studies comparing CTX + GC and MMF + GC.

### Analysis of inconsistency

In the evidence network diagram, CTX+GC, MMF+GC and CTX+TAC+GC formed a closed loop; thus, the direct evidence and indirect evidence of the three treatment regimens were consistently tested. The *Z* test result was indicated no inconsistency (P=0.931, P\>0.05).

### Detection of publication bias

A funnel plot was used to evaluate publication bias. The funnel plot was symmetrical in this analysis, and it can be considered that there was no publication bias in the direct comparison meta-analysis ([Fig. 3](#f3-etm-0-0-8257){ref-type="fig"}).

NMA results
-----------

### Comparison of treatment effect

The present results suggested that MMF+GC produced significantly higher overall responses (CR+PR), and MMF+GC (OR=2.58; 95% CI, 1.67--3.97), TAC+GC (OR=3.14; 95% CI, 1.05--9.43), CTX+LEF+GC (OR=3.05; 95% CI, 1.05--8.84), CTX+RTX+GC (OR=3.89; 95% CI, 1.60--9.45) and CTX+TAC+GC (OR=6.22; 95% CI, 1.93--20.05) had significantly higher overall responses than CTX+GC. In addition, the present results suggested that MMF+GC produced significantly higher overall responses, and MMF+GC (OR=4.13; 95% CI, 1.72--9.96), TAC+GC (OR=5.04; 95% CI, 1.16--21.97), CTX+LEF+GC (OR=4.89; 95% CI, 1.15--20.78), CTX+RTX+GC (OR=6.24; 95% CI, 1.66--23.39) and CTX+TAC+GC (OR=9.98; 95% CI, 2.23--44.56) had significantly higher overall responses than GC. There were no statistically significant differences in the effectiveness of any of the other regimens in the treatment of RLN ([Fig. 4](#f4-etm-0-0-8257){ref-type="fig"}).

### Comparison of safety

Comparison of infection suggested that the difference between MMF+GC and CTX+GC was statistically significant. Comparison of gastrointestinal reactions and leukopenia indicated no statistically significant differences between any of the groups ([Figs. 5](#f5-etm-0-0-8257){ref-type="fig"} and [6](#f6-etm-0-0-8257){ref-type="fig"}).

### Results sorting

In terms of efficiency, the maximum SUCRA value of CTX+TAC+GC was 80.6%, indicating that TAC+CTX+GC was likely to be the best currently used treatment. The maximum SUCRA values of CTX+GC were 67.8%, 80.1% and 65.4% for infection, gastrointestinal reaction and leukopenia, indicating that CTX+GC had the highest risk of adverse reaction ([Table II](#tII-etm-0-0-8257){ref-type="table"}).

Discussion
==========

At present, the cause of RLN remains elusive, but studies have indicated that non-compliance with treatment and lack of efficacy of the induction therapy regimens for LN may promote the development of RLN ([@b7-etm-0-0-8257]). However, there is no uniform guideline for the treatment of RLN patients; therapeutic drugs and treatment regimens depend largely on the patients\' condition and the clinician\'s experience. Therefore, the present study compared the effectiveness and safety of common therapeutic drugs for the treatment of RLN to provide a reference for the clinical prescription of drugs.

The traditional induction therapy used for LN is a combination of GC and intravenous CTX. The basic drug used in the induction phase is CTX at a sufficient dose, with a subsequent gradual dose reduction according to the patient\'s condition. In order to avoid the toxic effects of CTX, it recently was replaced with MMF ([@b30-etm-0-0-8257],[@b31-etm-0-0-8257]). Studies have indicated that, although the effectiveness of MMF in the treatment of LN is not different from that of CTX, it reduces the risk of ovarian failure associated with CTX ([@b32-etm-0-0-8257]). However, the present study indicated that MMF was more effective and was associated with less gastrointestinal adverse reactions than CTX in the treatment of RLN. In addition, MMF had a greater likelihood of reducing the risk of adverse effects, including infection and leukopenia, when compared with CTX.

The present study also indicated that TAC combined with CTX in the treatment of RLN was superior to the traditional regimen, but did not perform differently from MMF. This is consistent with previous results from an NMA of three drugs for LN ([@b33-etm-0-0-8257]). However, these three treatment regimens exhibited no difference in adverse reactions, including infection, leukopenia and gastrointestinal reactions. The mechanisms of action of MMF and tacrolimus are different; MMF reduces B-cell and T-cell proliferation, leads to antibody production, and recruitment of lymphocytes and monocytes, while tacrolimus reduces cytokine production and T-cell activation, and stabilizes the actin cytoskeleton of podocytes ([@b34-etm-0-0-8257]). Although the two drugs produce similar effects, tacrolimus is more expensive. RLN patients require long-term medication, and thus, the patients\' financial situation should also be considered when selecting an effective treatment.

In a prospective cohort study ([@b35-etm-0-0-8257]), a multi-target regimen (MMF+TAC+GC) was first proposed for the treatment of LN, and the incidence of complete remission were significantly higher than those with intravenous CTX, with fewer adverse events. The multi-target treatment also exhibited certain advantages in the treatment of RLN with not only a better treatment effect but also reduced hormone dosage and less resistance compared to traditional treatment regimen ([@b36-etm-0-0-8257],[@b37-etm-0-0-8257]). The present study compared three multi-target treatment regimens, namely the traditional regimen combined with RTX, the traditional regimen combined with LEF and the traditional regimen combined with TAC. The results suggest that the three multi-target treatment regimens are superior to the traditional treatment regimen and the ranking results suggested that the traditional regimen combined with TAC was the best of the nine regimens. It was also likely to have the lowest risk of infection in the treatment of RLN. Compared to traditional treatment regimen, multi-target therapy was not associated with any corresponding increase in adverse reactions. Furthermore, it not only produces an improved therapeutic effect but may also reduce the economic burden on patients to a certain extent ([@b38-etm-0-0-8257]). Thus, the clinical use of multi-target therapy should be promoted. However, with regard to the adverse reactions, including gastrointestinal reactions, infections and leukopenia, the multi-target therapy did not exhibit any difference from other regimens. However, this may be due to the small number of studies included.

In conclusion, the present study compared the effectiveness and safety of common therapeutic drugs and medication regimens in the treatment of RLN. The results indicated the superiority of the regimen of TAC+CTX+GC regarding its clinical efficacy in patients with RLN. Furthermore, the traditional treatment regimen (CTX+GC) had the highest probability of causing adverse effects among the nine interventions compared. However, the present study had certain limitations. First of all, for most of the regimens, the data for direct comparison were limited, resulting in insufficient evidence for indirect comparisons. Furthermore, previous studies have suggested that positive personal factors, including low-calorie diets and physical exercise, contribute to improved renal function ([@b39-etm-0-0-8257],[@b40-etm-0-0-8257]), but these factors were not considered in the present study and may have a potential impact on the results. Finally, in terms of adverse reactions, only infections, gastrointestinal reactions and leukopenia were analyzed, while other adverse reactions, including leukopenia, myelosuppression, alopecia, liver damage and menstrual disorders, were not analyzed due to incomplete data. Therefore, subsequent studies on RLN should focus on its adverse reactions when studying the curative effects.
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![Flow diagram of the selection of included studies.](etm-19-01-0665-g00){#f1-etm-0-0-8257}

![Network diagram of evidence for treatment efficacy of each regimen. The size of each node is proportional to the sample size of the individual treatment regimen; the widths of the connecting lines are proportional to the number of studies compared between the two regimens. GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.](etm-19-01-0665-g01){#f2-etm-0-0-8257}

![Funnel plot for assessment of publication bias or small sample effect. A, GC; B, CTX+GC; C, MMF+GC; D, LEF+GC; E, FK506+GC; F, CsA+GC; G, CTX+RTX+GC; H, CTX+LEF+GC; I, CTX+FK506+GC. GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.](etm-19-01-0665-g02){#f3-etm-0-0-8257}

![Comparison of the therapeutic effects of the regimens. The OR and 95% CI for comparison of the efficacy of each treatment regimen are provided. The results of the plots are read from top to bottom and from left to right. An OR \>1 indicates that the treatment on the top left is better than the comparative treatment. For instance, the effectiveness of TAC+CTX+GC is better than that of CTX+GC. The underlined and bold numbers indicate statistical significance. OR, odds ratio; GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.](etm-19-01-0665-g03){#f4-etm-0-0-8257}

![Comparison of infections after treatment according to each regimen. An OR \<1 means that the possibility of infection after treatment on the top left was lower than that after the comparative treatment. For instance, MMF+GC treatment of RLN had a lower risk of infection than CTX+GC. OR, odds ratio; GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.](etm-19-01-0665-g04){#f5-etm-0-0-8257}

![Comparison of gastrointestinal reactions and leukopenia after treatment with each regimen. Green indicates the comparison of gastrointestinal reactions after treatment with each regimen; light blue indicates the comparison of leukopenia after treatment with each regimen. GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.](etm-19-01-0665-g05){#f6-etm-0-0-8257}

###### 

Basic characteristics of the studies included.

  First author (year)   Sample size (n)   M/F      Treatment regimen                                                               Biopsy class              Duration (months)   Jadad score   (Refs.)
  --------------------- ----------------- -------- ------------------------------------------------------------------------------- ------------------------- ------------------- ------------- -----------------------
  Ma (2016)             64                40/24    GC, MMF (25 mg/day)+GC                                                          Unclear                   3                   3             ([@b9-etm-0-0-8257])
  Li (2012)             86                49/37    GC, MMF (25 mg/day)+GC                                                          Unclear                   3                   3             ([@b10-etm-0-0-8257])
  Wang (2015)           156               20/136   CTX (100 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                        Unclear                   6                   3             ([@b11-etm-0-0-8257])
  Zheng (2015)          31                18/13    CTX+GC, MMF(0.1 g/day)+GC                                                       Unclear                   3                   2             ([@b12-etm-0-0-8257])
  Dong (2014)           78                9/69     CTX (1,000 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                      Unclear                   24                  3             ([@b13-etm-0-0-8257])
  Liu (2013)            79                9/70     CTX (100 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                        III, IV,V                 24                  3             ([@b14-etm-0-0-8257])
  Liu (2009)            39                7/32     CTX (100 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                        IV                        24                  3             ([@b15-etm-0-0-8257])
  Yang (2008)           60                22/38    CTX (200 mg/m^2^)+GC, MMF (0.75 mg/day)+GC                                      Unclear                   6                   3             ([@b16-etm-0-0-8257])
  Zhen (2006)           40                26/14    CTX (1,000 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                      Unclear                   6                   3             ([@b17-etm-0-0-8257])
  Shi (2006)            53                5/48     CTX (400 mg/m^2^)+GC, MM F(1.5 g/day)+GC                                        IV                        6                   3             ([@b18-etm-0-0-8257])
  Li (2002)             40                1/39     CTX (400 mg/m^2^)+GC, MMF (1.5 g/day)+GC                                        Unclear                   3                   3             ([@b19-etm-0-0-8257])
  Mostafi (2010)        31                4/27     CsA (4 mg/kg/day)+GC, MMF (1.5 g/day)+GC                                        IV                        108                 3             ([@b20-etm-0-0-8257])
  Lu (2017)             74                25/49    CTX (1,000 mg/m^2^)+GC, TAC (2 mg/day)+GC                                       Unclear                   12                  4             ([@b21-etm-0-0-8257])
  Liu (2016)            30                3/27     LE F(30 mg/day)+GC, TAC (2 mg/day)+GC                                           III, IV, V, III+V, IV+V   6                   3             ([@b22-etm-0-0-8257])
  Xiang (2017)          60                7/53     CTX (400 mg/m^2^)+GC, CTX (400 mg/m^2^)+ LEF (20 mg/day)+GC                     IV                        6                   4             ([@b7-etm-0-0-8257])
  Liang (2014)          50                13/37    CTX (400 mg/m^2^)+GC, CTX (400 mg/m^2^)+ TAC (3.5 mg/day)+GC                    Unclear                   6                   3             ([@b23-etm-0-0-8257])
  Yi (2014)             27                5/22     CTX (800 mg/m^2^)+GC, CTX(800 mg/m^2^)+ RTX (375 mg/m^2^)+GC                    III+V, IV+V               6                   3             ([@b24-etm-0-0-8257])
  Zhang (2015)          84                --       CTX (800 mg/m^2^)+GC, CTX (800 mg/m^2^)+ RTX (375 mg/m^2^)+GC                   III+V, IV+V               12                  4             ([@b25-etm-0-0-8257])
  Mo (2009)             45                4/41     CTX (400 mg/m^2^)+GC MMF (1.5 g/day)+GC CTX (400 mg/m^2^)+TAC (3.5 mg/day)+GC   IV, V, III+V, IV+V        6                   2             ([@b26-etm-0-0-8257])

M/F, male/female; GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A; d, day.

###### 

SUCRA values (%) for treatment efficacy and safety of each regimen.

  Treatment regimen   Efficacy   Infection   Gastrointestinal reaction   Leukocyte decline
  ------------------- ---------- ----------- --------------------------- -------------------
  TAC+CTX+GC          80.6       15.8        24.1                        N.A.
  LEF+GC              68.9       N.A.        23.3                        N.A.
  CsA+GC              65.9       N.A.        N.A.                        N.A.
  RTX+CTX+GC          64.3       55.0        59.5                        N.A.
  TAC+GC              54.8       N.A.        36.3                        42.4
  LEF+CTX+GC          54.1       69.1        79.1                        59.0
  MMF+GC              45.1       42.3        47.6                        20.2
  CTX+GC              12.7       67.8        80.1                        65.4
  GC                  3.6        N.A.        N.A.                        63.0

A greater SUCRA value indicates higher efficacy; thus, the effect of TAC+CTX+GC was indicated to be the best. A lower SUCRA value indicates a lower risk of adverse reactions; thus, the risk of infection with TAC+CTX+GC was the lowest. N.A. indicates failure to enter the analysis data and no corresponding value is provided. M/F, male/female; GC, glucocorticoid; CTX, cyclophosphamide; MMF, mycophenolate; TAC, tacrolimus; LEF, leflunomide; RTX, rituximab; CsA, cyclosporine A.
